The protective effect of the u2-receptor antag onist idazoxan against neuronal damage in the neocortex and in the hippocampal CAl region was studied in rats exposed to 10 min of incomplete forebrain ischemia. When administered i. v. immediately after ischemia (0.1 mg/kg) and subsequently for 6 h (10 f,1g/kg/min), idazoxan
significantly reduced neuronal damage in the hippocam pus (from 84 to 26%) and in the vulnerable parts of the neocortex (from 15 to 1 %). The bolus dose alone provided no significant protection. When idazoxan administration was delayed for 30 min, no significant protection was noticed in the neocortex, and the effect in the hippocam pus was ambiguous. A transient elevation of plasma cor ticosterone levels was induced during ischemia. Idazoxan administration for 2 h did not affect postischemic changes in corticosterone levels compared with saline infusion.
Idazoxan 00-7 _10-4 M) did not influence the in vitro binding to glutamate receptors in brain slices. Thus, the In certain brain areas, selectively vulnerable to ischemic insults, such as the hippocampus and the neocortex, cellular damage develops after a time interval and is visible by light microscopy 48 h postischemia (Kirino, 1982; Pulsinelli et aI. , 1982a; Smith et aI., 1984a) . Thus, in these areas, pharma cological treatment may be expected to have a po tential influence on the final outcome of the injury when administered after the ischemic insult.
Glutamate and possibly other excitatory amino protective effect of idazoxan cannot be explained by sup pression of the plasma corticosteroid levels or via an an tagonistic effect on glutamate receptors. Idazoxan appar ently protects neurons when given during the first hours of postischemic reperfusion, while histopathological ne crosis of neurons becomes visible 48-72 h after ischemia.
Detrimental processes causing delayed neuronal death occur in the early postischemic phase and can be influ enced by adrenoceptor ligands. Idazoxan may protect by several mechanisms but probably exerts its protective postischemic effect mainly through an increased norad renergic neuronal activity and an elevation of extracellu lar noradrenaline (NA) levels in the brain. The favorable effects of NA may either be due to inhibition of excito toxic neurotransmission or activation of survival promoting and trophic processes. Key Words: Noradren aline-Idazoxan-Ischemic brain damage-Adrenocep tors-Rats.
acids have been proposed to be main factors elicit ing neuronal damage following ischemia and hypo glycemia (Wieloch, 1985; Rothman and Olney, 1986; Choi, 1988) , while transmitters and modula tors considered to be mainly inhibitory, such as nor adrenaline (NA) and adenosine, exert a protective influence in the central nervous system (Wieloch et aI., 1986; Rudolphi et aI., 1987 ).
The NA system is a seizure-depressant and pro tective system in the CNS (Mason and Corcoran, 1979; Nevander et aI., 1986) . Furthermore, chemi cal destruction of the ascending central noradrener gic system by lesions of the brain stem nucleus locus ceruleus has been shown to aggravate postischemic damage after cardiac arrest in rats (Blomqvist et aI., 1985) . Pharmacological depletion of NA from gerbil brain by administration of the neurotoxin DSP4 [N (2-chloroethyl)-N-ethyl-2-bromobenzylamine] also increased neuronal damage in the hippocampus fol lowing transient global ischemia (Davis et aI., 1989) . The ganglionic blocker trimetaphan, which curtails the plasma NA rise during ischemia, aggravates ischemic brain damage in rats, while intravenous infusion of NA ameliorates it (Koide et aI., 1986) .
The (l 2 -antagonists stimulate the firing rate of the noradrenergic neurons in the locus ceruleus (LC) by blocking autoreceptors on the dendrites, soma, or axon terminals of these cells (Cedarbaum and Aghajanian, 1976; Freedman and Aghajanian, 1984) . Idazoxan (2-[2-( 1,4-benzodioxanyl) ]-2imidazoline HC1) is a potent and selective antago nist at (l 2 -adrenoceptor sites (Doxey et aI., 1983) with an (l 2 /(l) selectivity ratio of 288 compared to 45 for yohimbine. In contrast to yohimbine, it is de void of activity at dopamine, serotonin, and hista mine receptors (Dabire, 1986) . Idazoxan as well as yohimbine increases the turnover rate of norepi nephrine in rat cortex; however, unlike yohimbine, idazoxan does not increase the turnover rate of dopamine (Walter et aI., 1984; Pettibone et aI., 1985) .
In a previous study, we were able to show a pro tective effect of idazoxan against neuronal damage after transient forebrain ischemia in rats (Gustafson et aI., 1989) . Idazoxan was given systemically for 48 h starting immediately after 10 min of incomplete forebrain ischemia to ensure coverage of the whole maturation period of neuronal damage in the hip pocampus.
The aim of the present study was to investigate further the temporal aspects of the protective ef fects of idazoxan, both in terms of duration of treat ment and delay of postischemic administration of the drug, and to clarify some aspects of the mech anisms of the cellular protection provided by ida zoxan.
MATERIALS AND METHODS

Animals and experimental groups
Male Wistar rats (weight: 250-375 g; SBF strain; M�llegaards Avlslaboratorium, Copenhagen, Denmark) were used for all experiments. They were fasted over night but had free access to tap water before anesthesia. In each experiment, all animals were subjected to 10 min of incomplete forebrain ischemia by a combination of bi lateral carotid artery clamping and induced hypovolemic hypotension (see below).
Histopathology-part 1
Seventeen rats were used. Idazoxan was given to eight animals as an intravenous bolus dose (0. 1 mg/kg) imme diately upon recirculation followed by an i.v. infusion (10 fl-g/kg/min) for 6 h. Nine animals were used as controls and received saline in corresponding volumes.
J Cereb Blood Flow Metab, Vol. 10, No. 6, 1990 Histopathology-part 2 Twenty rats were used. Idazoxan was given only as the bolus dose (0. 1 mg/kg) immediately after recirculation (n = 10). Controls (n = 10) received saline in equal vol umes.
Histopathology-part 3
Twenty-four rats were subjected to ischemia in this part of the experiment. A bolus dose of idazoxan (0. 1 mg/kg) given after 30 min of recirculation was followed by 24 h of idazoxan infusion (10 fl-g/kg/min; n = 12). Con trols (n = 12) received saline in equal volumes.
Anesthesia and operative procedure
Following anesthetic induction with 3-4% isoflurane in a 70% N20/02 mixture, the rats were endotracheally in tubated (Intramedic PE 240) and connected to a Starling type respirator. Anesthesia was maintained with isoflu rane 1.5% in N20/02• Both common carotid arteries were exposed through a neck incision and prepared for later occlusion. A silicone catheter (inner diameter 0.03 in, outer diameter 0.05 in) was inserted into the right external jugular vein and advanced 4--5 cm to reach a position suited for rapid withdrawal of blood later in the proce dure. The tail artery was cannulated for continuous mon itoring of blood pressure and for intermittent sampling of arterial blood. A tail vein was cannulated to allow i. v. injection of drugs. A pair of needle electrodes were in serted through small skin incisions into the temporalis muscle bilaterally to obtain an interhemispheric EEG. Thermistors were placed on the skull surface and in the rectum. Following the operating procedures, the rats were allowed a 30 min stabilization period during which isoflurane was removed from the anesthetic gas mixture and the muscle relaxant vecuronium bromide (Norcuron, Organon Teknika, Boxtel, Holland) was added as inter mittent i. v. doses of 1.0 mg/kg. The rectal and skull tem peratures were kept at close to 37°C using a heating lamp and the arterial blood gases controlled within normal lim its. Blood glucose was measured directly, using Glucostix reagent strips and a reflectometer system (Ames Co., Elkhart, IN, U.S.A.). Heparin (50 IU) was given intrave nously as an anticoagulant.
Cerebral ischemia was induced and maintained for 10 min by a combination of bilateral carotid clamping and reduction of arterial blood pressure by rapid withdrawal of blood. The procedure is a modification of a method described earlier from this laboratory (Smith et al., 1984b) , omitting the use of a ganglion blocker (tri metaphan). Immediately before the ischemia, blood was withdrawn through the silicone catheter to reach an MABP of about 70 mm Hg. Both carotid arteries were clamped, and blood was then further withdrawn, and if necessary reinfused, to reach and maintain a stable MABP of 50 mm Hg throughout the ischemia period. The onset of cerebral ischemia was defined as the time of cessation of EEG activity, usually within 1 min after clamping. At the end of the ischemia period, the vascular clamps were removed and the withdrawn blood was re infused. Sodium bicarbonate (0.5 ml of a 0.6 M solution) was given intravenously. The jugular vein catheter was removed and replaced by a polyethylene catheter (Portex PE 50) that was advanced 3 cm into the superior vena cava. The catheter exited in the dorsal neck and was con nected to a syringe placed in a minipump (Carnegie Med icin AB, Stockholm, Sweden), via a swivel connector (Carnegie Medicin AB). To prevent twisting and kinking, the catheter was passed through a metal spring placed between the animal and the swivel connector. The spring was attached with sutures to the skin of the rat, allowing free movements in the cage without disturbing the drug infusion.
During the immediate recovery period after the opera tion, the blood pressure monitoring continued, the arte rial PaOZ' PaCOZ' and pH values were checked, and the animals allowed to regain consciousness and spontaneous respiration. Extubation was feasible 10-15 min after the end of ischemia, and the rats were then transferred to cages. The spring and catheter device did not seem to restrain movements or affect the postischemic behavior of the animals.
Histological assessment of neuronal damage
The histological studies were done on animals after a survival time of 7 days following the ischemic insult. The rats were anesthetized with halothane, tracheostomized, and connected to a respirator. The brains were perfusion fixed via the ascending aorta with a solution of 4% form aldehyde in 0.1 M phosphate buffer, preceded by a short saline rinse. Both solutions were prewarmed to 3rc. The brains were removed and subsequently stored at 4°C in formaldehyde solution until further processed.
The preparation and staining of the brain sections with celestine blue-acid fuchsin have been described previ ously (Auer et aI., 1984) . Sectioning intervals were adapted to obtain standard levels of the caudate nucleus, neocortex, and the hippocampus throughout its extent. The quantification of hippocampal injury was done by counting normal and necrotic cells in the dorsal hippo campal CA 1 region approximately 3.8 mm caudally from the bregma (according to the atlas by Paxinos and Wat son, 1982) . Neocortical areas were examined throughout the brain sections, as the cellular necrosis was much less extensive than in the hippocampus and unevenly distrib uted. The most severely damaged neocortical area, usu ally found temporally about 5 mm caudally from the bregma and dorsal to the rhinal fissure, was used for cell counting. As in the hippocampus, both normal and ne crotic cells were counted. With the staining procedure adopted, the necrotic neurons appear bright red on ex amination under the light microscope, and the extent of injury was expressed as a percentage of necrotic neurons of the total number in each area examined at a magnifi cation of x400.
Slight interhemispheric differences in neuronal necro sis without any side preference are relatively common in experimental as well as in control groups. For each brain, the average counts in percent from the two hemispheres are presented and statistically analyzed.
Corticosterone measurements
In a separate group of animals (n = 12), arterial blood samples of 80-100 fLl were withdrawn at the following times: 30, 20, and 10 min prior to ischemia, at the onset, after 5 min and 10 min of ischemia, and at 10,20,30,60, and 120 min of reperfusion following ischemia. A total of 11 samples were obtained from each animal. Idazoxan was given to six animals as a bolus (0.1 mg/kg) at reper fusion, followed by infusion (10 fLg/kg/min) i. v. for 2 h. The control group (n = 6) received saline in correspond ing volumes. The blood samples were centrifuged and plasma was frozen to -80°C for later analysis.
Corticosterone was measured by a radioimmunoassay using antiserum (International Laboratory Services, Lon don, U.K.) on unextracted pepsin-treated plasma (Abra ham et aI., 1977; Thorell and Larsson, 1978) .
RadioIigand binding
The possible effects of idazoxan on total [3H]glutamate binding, N-methyl-D-aspartate (NMDA)-displaceable [3H]glutamate binding (Monaghan et aI., 1983) , [3H]_ MK -801 binding (Bowery et aI., 1988) , or strychnine insensitive eH]glycine binding (Bristow et aI., 1986 ) to brain slices were assessed in a separate group of animals. Rats (n = 4) were decapitated and their brains were quickly removed, frozen in isopentane chilled to -50°C, and stored at -80°C. Following sectioning (6 fLm) at -20°C, coronal brain sections from the dorsal hippocam pal area were mounted onto gelatin-permanganate subbed microscope slides and incubated with the appro priate tritiated ligand in the presence of idazoxan in in creasing concentrations (0, 0.1, 0.5,1,5, 10,50, and 100 fLM). Following the radioligand incubation, the sections were rinsed in four baths of ice-cold buffer over 30 s and wiped off from the slide into scintillation vials, using glass fiber filters (Whatman GF/B), for subsequent scintillation counting of the tritium activity. 
Statistical analysis
Histopathology
The lack of normal distribution together with a rela tively small number of observations (n � 12 in each group) made the Student's t test less suitable for a statis tical analysis in some of the experimental groups. A two sample rank sum test was considered but was not em ployed due to accumulation of extreme values (severe hippocampal or no cortical damage in several animals) with many ties. In these cases, we used Fischer's exact test on each group divided into two subgroups with dif ferent severity scores (extensive damage and less than extensive damage) with defined limits between scores. In the hippocampus, extensive damage was defined as >50% necrotic cells. In neocortex, the corresponding limit was set at 8%. For reasons of simplicity, the arith metic mean and SD were used for several groups in the text.
Physiological variables, corticosterone levels, and radioligand binding
For these parts of the study, a two-tailed Student's t test was used.
RESULTS
Physiological variables
The physiological variables of the experimental groups in part I and part 2 of the histopathology study are shown in Table 1 . In all groups, MABP was measured continuously until the animals were extubated and allowed to wake up. The values im mediately before and 15 min after the ischemia pe riod are presented. A tendency to a transient in crease in postischemic blood pressure was noticed in all groups, reaching statistical significance (p < 0.05) only in the idazoxan group of part 2 (bolus dose). The mean postischemic increase in MABP did not differ significantly between saline-treated and idazoxan-treated animals.
The rectal temperature before and 15 min after ischemia was kept close to 37.0°C and did not change significantly during this period or differ be tween groups. Blood glucose levels decreased slightly 15 min after ischemia compared with pre ischemic levels. No difference between idazoxan and control groups was found.
Histopathology
Photomicrographs of the hippocampal CA 1 re gion in rats after 1 week of postischemic survival with and without idazoxan treatment following 10 min of ischemia have been shown in an earlier pub lication (Gustafson et aI., 1989) . Normal hippocam pal and neocortical pyramidal cells are rounded with preserved nuclei and prominent nucleoli. Dam aged or necrotic neurons appear as shrunken cells, often triangular-shaped, brightly red from taking up acid fuchsin stain and with condensed nuclei. Mac rophages often appear in clusters around cortical necrotic neurons, while in the hippocampus, mac rophages are found in the stratum radiatum along dendrites of the pyramidal cells.
Part 1
In animals that received idazoxan as a bolus dose (0. 1 mg/kg Lv.) followed by a continuous infusion (10 f.Lg/kg/min) for 6 h, the percentage of neuronal necrosis in the hippocampal CA 1 region was 26 ± 16% (mean ± SD; range of 10-50%). In saline treated animals, 84 ± 8% (range of 72.5-95%) of CAl neurons were necrotic (Fig. 1A) . The individ ual values within each of these two groups have a sufficiently normal distribution to allow the appli cation of Student's two-tailed t test and to establish the confidence interval for the mean difference be tween groups. The difference is highly significant (p = 0.000 1) and a 95% confidence interval for the mean group difference is 58.8 ± 12.8%. In the most severely damaged area of the neocortex, the cell counts were unevenly distributed with six animals of eight in the idazoxan group totally undamaged. One percent (range of 0-6%) of the necrotic neurons were found in idazoxan-treated animals, compared to 15 ± 9% (range of 4-25%) in control animals. Fischer's exact test applied to cortical cell counts shows a significant difference (p = 0.009).
Part 2
When only a bolus dose (0. 1 mg/kg i. v.) of ida zoxan was given immediately following ischemia, neuronal necrosis in the CAl ranged from 22.5% to 95%, with a mean value of 67 ± 27% (SD) (Fig. lB) compared to the saline-treated group, where 85 ± 15% neuronal damage was found (range of 50-95%). With Fischer's exact test, no significant difference appeared between treated and nontreated animals; nor was any significant difference between groups noticed in the neocortical areas (14 vs. 12%).
Part 3
In the experimental group where idazoxan admin istration started with a bolus dose 30 min after reperfusion and continued as an infusion for 24 h, the results in the hippocampus were found to be somewhat equivocal. While in the saline-infused an imals neuronal damage in the hippocampus was as high as in other control groups (83 ± 11%, range of 65-95%), the results from the idazoxan-treated group seemed to fall into two subgroups (Fig. Ie) .
In 7 of 12 animals, no reduction in necrotic neurons was seen (77 .5-95%). In the remaining five animals, only 1-25% damage was noticed. When applying the two-tailed Fischer's exact test to treated vs. control animals, the p value was found to be 0.037, i.e., a statistically significant difference exists, in dicating a protective idazoxan effect in the hippo campus. In the cortex, the same statistical test could not detect any significant difference between treated and nontreated animals. However, as can be seen in the figure, more undamaged brains were found in the idazoxan group than among controls. In sections from the caudate nucleus, no cell dam age was found in any of the experimental groups.
Corticosterone levels
Plasma levels of corticosterone in anesthetized and operated animals 30 min prior to ischemia were 595 ± 237 (mean ± SD) ng/ml in the control group (n = 6) and 619 ± 113 ng/ml in the group to receive idazoxan later (n = 6) ( Fig. 2) . Immediately preced ing ischemia, the corresponding values were 630 ± 168 and 757 ± 176 ng/ml, respectively. During isch emia, a 60% increase was noticed (p < 0.00 1; Stu dent's paired t test), returning to preischemic levels within 10 min of reperfusion. Two hours post ischemia, the corticosterone levels in the idazoxan- and idazoxan-treated rats after 7 days of survival following 10 min of two-vessel occlusion brain ischemia. (A) Idazoxan as a bolus dose (0.1 mg/kg) immediately after ischemia followed by 6 h of Lv. infusion (10 �g/kg/min). The difference between groups is significant (p = 0.0001 for hippocampus, p = 0.009 for neocortex; Student's unpaired, two-tailed t test). (8) Ida zoxan as bolus dose (0.1 mg/kg) without subsequent infu sion; no significant difference between groups; Fischer's ex act test for two subgroups. (C) Idazoxan as bolus dose (0.1 mg/kg) given 30 min after ischemia followed by Lv. infusion (1 0 �g/kg/min) for 24 h. In the hippocampus, the difference between groups is significant (p = 0.037; Fischer's exact test). Each dot represents one brain, Le., the arithmetic means of counts from the two hemispheres.
infused group were 59% higher (p < 0.05) than in the saline group. However, this difference was in herent from the sampling periods preceding drug treatment. When corticosterone levels from pre treatment samples were compared with the levels after 2 h of treatment (sample no. 6 vs no. 11, Fig.  2) , no difference between idazoxan-and saline treated animals was found (paired Student's t test). 
Radioligand binding
In concentrations from 10-7 to 10-4 M, idazoxan did not affect total [3H]glutamate binding, NMDA displaceable eH]glutamate binding to brain slices (Fig. 3A,B) , or eHJMK-801 binding (n = 2, data not shown). Strychnine-insensitive eH]glycine binding was also not affected by idazoxan in con centrations between 10 -7 and 10 -5 M (Fig. 4) . However, at higher idazoxan concentrations (10 -4 M), a tendency of a reduced specific glycine binding could be discerned.
DISCUSSION
In this study, we confirm our previous findings (Gustafson et aI., 1989 ) that delayed neuronal ne crosis in the rat neocortex and hippocampus can be ameliorated by postischemic administration of ida zoxan. A bolus dose of idazoxan directly following ischemia was not efficacious, and a delay of ida zoxan administration to 30 min after the ischemic period decreased the potency of protection. �his demonstrates that in the early phase of reperfuslOn, adrenoceptor-mediated phenomena can influence ischemic brain damage and may be affected by pharmacological intervention. In the following, we will discuss some of the implications of these find ings including possible mechanisms underlying the protective effect of idazoxan, the rationale be . hind the protection by early rather than late postIsch- emic administration of idazoxan, and the involve ment of the noradrenergic neurotransmitter system in the mechanisms of delayed neuronal death. In the CNS, !X 2 -adrenoceptors have been found in high density in the LC (Young and Kuhar, 1980) , a pontine nucleus containing approximately one-half of all noradrenergic neurons in the rat brain, and from which all NA-containing afferents to the neo cortex and hippocampus originate. Noradrenaline can regulate the activity of the LC via tonic "col lateral inhibition" (Cedarbaum and Aghajanian, 1976) . !X 2 -Receptor agonists decrease and idazoxan and other antagonists increase the activity of the LC neurons (Svensson et aI., 1975; Aghajanian et al., 1977; Cedarbaum and Aghajanian, 1978; Simson and Weiss, 1987) by their actions on dendrosomatic and axonal autoreceptors. Idazoxan was found to counteract the inhibitory effect of clonidine on spontaneous firing of LC neurons, when the drugs were given systemically or applied locally by micro iontophoresis (Freedman and Aghajanian, 1984 !. Evidence has also been provided that presynaptic !X 2 -receptors on noradrenergic nerve terminals play a cardinal role in the regulation of synaptic NA re lease in rats (Curet et aI., 1987; Dennis et aI., 1987) . These presynaptic !X 2 -autoreceptors appear to rep resent only a small fraction of the total number of !X 2 -adrenoceptors in the brain (U'Prichard et aI., 1979; Pimoule et aI., 1983; Gross et aI., 1985) , but seem to be of great functional importance for the regulation of noradrenergic synaptic activity. Ida zoxan administration increases the extracellular levels of NA. When measured by intracerebral mi crodialysis in anesthetized rats, the extracellular levels of NA in the cerebral cortex increased, when either the ascending noradrenergic fibers from the LC were electrically stimulated or idazoxan was given (L'Heureux et aI., 1986) . In awake, unre strained rats, the same dose of idazoxan increased cortical NA levels three to four times (Dennis et aI., 1987) . While certain neuropeptides are known to be colocalized with NA in noradrenergic terminals (H6kfelt et ai., 1984; Moore and Gustafson, 1989) , idazoxan-stimulated release of neuropeptides in the brain has not been reported.
During ischemia, the NA system is activated. A massive increase in hippocampal NA release during 20 min of forebrain ischemia has been demonstrated (Globus et ai., 1989) , and we have recently found that idazoxan prolongs the increase in hippocampal NA release early in the postischemic period (Gustafson et ai., in preparation) . Thus, idazoxan may exert its cerebroprotective effect against the development of postischemic injury by blocking u 2 -receptors on pre-or postsynaptic elements, thereby increasing extracellular levels of NA. It should be borne in mind, however, that U 2adrenoceptors are also localized on terminals of other CNS transmitter systems, so-called U 2 -het eroreceptors. Such receptors are found on dopami nergic (Dubocovich, 1984) , serotoninergic (Frank huyzen and Mulder, 1980) , GABAergic (Pittaluga and Raiteri, 1987) , glutamatergic (Crowder and Bradford, 1987) , and cholinergic (Beani et ai., 1978) neurons, and their physiological and pathophysio logical roles in neurotransmission remain to be clar ified. Furthermore, u 2 -adrenergic receptor hetero geneity has been demonstrated over the last few years (Bylund, 1985; Boyajian and Leslie, 1987; Hamilton et ai., 1988) , with idazoxan binding to dif ferent receptor subtypes than other u 2 -antagonists.
The effects of N A on cellular function when act ing on brain adrenoceptors are complex. In normal brain, the transmitter effects on neuronal activity can be inhibitory (Segal and Bloom, 1976) as well as excitatory Nicoll, 1986, 1988) or mixed (Mueller et ai., 1982; Pang and Rose, 1987; Mynlieff and Dunwiddie, 1988) , probably due to ac tivation of different adrenoceptor types and sub types, partly depending on ligand concentration and receptor location in the brain, and on stimulation intensity. The postsynaptic receptor(s) mediating the protective effects of NA have not been defined, and a discussion on the involvement of different adrenoceptors would be speculative considering the fact that the properties of the receptors may be sig nificantly altered in the postischemic brain. For ex ample, the u-receptors are desensitized in the post ischemic gerbil brain .
The fact that idazoxan is protective if adminis tered early after ischemia suggests that increased central noradrenergic activity may mitigate delete rious events during the initial recirculation phase. Assuming that the protective effect of idazoxan is mediated through increased synaptic levels of NA (or NA + neuropeptides colocalized with NA), at least two different modes of protective action can be envisaged. The inhibitory seizure-depressant properties of NA may prevent a postischemic hy peractivity, thus mitigating cytotoxicity of excitato ry neurotransmission (Rothman and Olney, 1987) . However, the postischemic metabolic rate in brain regions subjected to moderate or severe ischemia, expressed as glucose utilization (local CMRglc), was decreased during 1 to 48 h (Pulsinelli et ai., 1982b; Kozuka et ai., 1989) , and neuronal hyperactivity was not recorded in the hippocampus following ischemia (Buzsaki et ai., 1989) . It is thus conceiv able that NA may protect against ischemia by en hancing survival-promoting and trophic processes (Wieloch et ai., 1986) . Increased neuronal activity following amphetamine treatment has long ago been proposed as recovery promoting after focal isch emia, and this effect has been confirmed in recent years (Feeney et ai., 1982; Hovda and Feeney, 1984; Crisostomo et ai., 1988; Hurwitz et ai., 1989 ). An intraventricular infusion of NA, but not of dopamine, mimics the amphetamine effect (Boye son . Goldstein (1989) reported a facilitation of recovery after unilateral cortical le sions in rats following both d-amphetamine and ida zoxan treatment, supporting the hypothesis that the effects of amphetamine are mediated through the noradrenergic transmitter system.
When discussing the underlying mechanisms of idazoxan protection, effects on targets other than central noradrenergic receptors must be consid ered. Idazoxan has affinity to noradrenergic binding sites in the brain as recently demonstrated (Erns berger et ai., 1987; Convents et ai., 1989; Wikberg, 1989) . Until now, the functional roles of these re ceptor sites have not been established. Idazoxan also inhibits u 2 -adrenoceptors in peripheral tissue as well as in the central nervous system. Thus, a possible impact of idazoxan on cardiovascular func tion and blood hormone levels must be recognized. Effects on temperature, blood glucose levels, and postischemic cerebral blood flow should also be considered. As shown in Table 1 , blood pressure, rectal temperature, and blood glucose in the present study did not differ between treated and nontreated groups during the first 15 min after ischemia, i.e., as long as measurements were continued before re turning the animals to their cages after extubation. Blood pressure did not change during a 4-h infusion of idazoxan to awake rats at doses identical to those in the present study (T. L. Berridge, personal com munication). Effects of idazoxan on CBF seem less probable since lesions of the LC did not alter CBF during hypercapnia (Dahlgren et ai., 1981) or in the postischemic phase (Blomqvist et ai., 1984) .
A possible influence on adrenocorticotropic hormone (ACTH)-corticosterone secretion by NA and indirectly by idazoxan should also be scruti nized. The paraventricular nucleus of the hypothal amus, which secretes corticotropin-releasing factor into the hypophysial-portal circulation as a signal for ACTH secretion, receives noradrenergic affer ents from the LC (Sawchenko and Swanson, 1982) . Both inhibitory (Weiner and Ganong, 1978; Tuomisto and Mannisto, 1985) and stimulatory (Fehm et aI., 1980; Szafarczyk et aI., 1987) effects of NA on ACTH production mediated by adreno ceptors have been demonstrated. In addition, cate cholamines have been proposed to enhance the re lease of neuronally localized corticosterone by act ing on l3-receptors (Dietl, 1987) . As shown by Sapolsky and Pulsinelli (1985) , postischemic admin istration of corticosterone to adrenalectomized rats subjected to 20 min of four-vessel occlusion isch emia significantly aggravated neuronal damage in all brain regions. In the present study, postischemic corticosterone levels did not decrease in the ida zoxan-treated animals, which lessens the probabil ity of an idazoxan action on the ACTH-corti costerone system as a cause of the protective effect.
In some models of cerebral ischemia, glutamate antagonists decrease ischemic neuronal damage (Si mon et aI., 1984; Park et aI., 1988; Meldrum and Swan, 1989) . Thus, another possibility to be con sidered is that the protective effect of idazoxan in the present investigation could be associated with a glutamate receptor antagonism, although no such effect has to our knowledge been described. The present study shows that idazoxan in increasing concentrations from 10�7 to 1O�4 M failed to dis place eH]glutamate total binding or binding to NMDA receptors and also failed to displace eH]MK-80 1 from the calcium channel site operated by the NMDA receptor, arguing against idazoxan as a glutamate antagonist. A tendency of a displace ment of glycine binding noticed only with high con centrations of idazoxan probably has no relevance for the in vivo cerebroprotective effect.
In conclusion, early but not late administration of idazoxan in the recirculation phase after ischemia is protective against hippocampal and neocortical neuronal damage, suggesting that early postisch emic events are crucial in the development of de layed neuronal death. The mechanisms by which idazoxan acts at the pre-or postsynaptic receptor level remain to be clarified. The interpretation fa vored by us is that the protective effect by idazoxan on ischemic brain damage is exerted through an in creased noradrenergic neuronal activity and an el evation of extracellular NA during the early post-J Cereb Blood Flow Metab. Vol. 10, No. 6, 1990 ischemic period. Whether NA acts directly on vul nerable neurons or non-neuronal elements or via effects on the release or uptake of other transmit ters has yet to be determined. Inhibitory effects on excitotoxic neurotransmission or a reversal of post ischemic cerebral neuronal depression are possible alternatives to explain a favorable influence of NA to prevent cellular damage.
